share_log

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%), etc.

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%), etc.

Invivyd | SC 13G/A：超过5%持股股东披露文件(修正)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%)等
美股SEC公告 ·  2024/11/09 05:25

Moomoo AI 已提取核心信息

On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
2024年9月30日，包括GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., 以及alphabet inc在内的一组相关实体，合称为申报人，向美国证券交易委员会提交了一份修正声明，报告他们已停止拥有Invivyd, Inc. 5%以上的普通股权益。 这份修正声明名为表格13G/A，指示截至2024年9月30日，申报人共同拥有Invivyd的已发行普通股...展开全部
2024年9月30日，包括GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., 以及alphabet inc在内的一组相关实体，合称为申报人，向美国证券交易委员会提交了一份修正声明，报告他们已停止拥有Invivyd, Inc. 5%以上的普通股权益。 这份修正声明名为表格13G/A，指示截至2024年9月30日，申报人共同拥有Invivyd的已发行普通股0.0%，这是基于2024年8月1日尚未流通的119,442,635股股份进行计算的。 初始声明是在2022年2月14日提交的，这次最新的修正证实了所有权状态的变化。 Invivyd, Inc., 以前称为Adagio Therapeutics, Inc., 总部位于马萨诸塞州沃尔瑟姆，而申报人则与设在特拉华州的企业有关，主营业务办公地点位于加利福尼亚州芒廷维尤市1600号Amphitheatre Parkway。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间